Printer Friendly

BRADLEY PHARMACEUTICALS REPORTS RECORD QUARTERLY SALES AND SUCCESSFUL COMPLETION OF I.P.O. OVERALLOTMENT OFFERING

 BRADLEY PHARMACEUTICALS REPORTS RECORD QUARTERLY SALES
 AND SUCCESSFUL COMPLETION OF I.P.O. OVERALLOTMENT OFFERING
 FAIRFIELD, N.J., Jan. 6 /PRNewswire/ -- Bradley Pharmaceuticals, Inc. (NASDAQ: BPRXA), today reported that sales for the third quarter ending September 1991 rose 35.2 percent to approximately $278,000 from the similar period in 1990. Sales for the nine months rose almost 24 percent to approximately $726,000. While most product lines showed satisfactory increases, the recent acquisition of Duadacin(R) capsules from Hoechst-Roussel Pharmaceuticals Inc. in August 1991 significantly attributed to the rapid rise in the third quarter and nine month results.
 BRADLEY PHARMACEUTICALS, INC.
 Three months ended September 1991 September 1990
 Sales revenue $ 278,000 $ 206,000
 Profits (loss) $ (7,212) $(210,000)
 Net loss per share $(.02) $(.47)
 Shares outstanding 450,000(A) 450,000(A)
 Nine months ended September 1991 September 1990
 Sales revenue $ 726,000 $ 586,000
 Profits (loss) $(257,000) $(544,000)
 Net loss per share $(.57) $(1.21)
 Shares outstanding 450,000(A) 450,000(A)
 (A) -- An additional 450,000 shares are held in escrow.
 I.P.O. Overallotment Successfully Sold
 Bradley Pharmaceuticals, Inc., also reported that the entire overallotment of 112,500 units were sold by the underwriter D.H. Blair & Co., Inc., members of the New York Stock Exchange. The original offering of 750,000 units (two common, two "A" warrant and one "B" warrant) was completed on Nov. 12, 1991.
 New Board Member Added
 In addition, Richard Audet, chief financial officer, has been named to the board of directors for a three-year term. This increases the board to six members.
 New International Sales and Marketing Head Added
 Also of importance, Bradley Pharmaceuticals announced the appointment of James Prochowski, vice president-international sales and narketing, to head up its recently expanded international network, including the Alero Corporation in Puerto Rico and Woo Yang Corp. in Korea. Prochowski held previous positions as director of business development for the Pacific Region at Wyeth-Ayerst, St. Davids, Pa., and director of marketing development, cardiovascular products worldwide, at Warner-Lambert, Morris Plains, N.J.
 Bradley Pharmaceuticals, Inc., markets both prescription and non- prescription pharmaceuticals.
 -0- 1/6/92
 /CONTACT: Gene Goldberg, executive vice president of Institute for Medical Information, 201-227-5599; or Richard Audet, chief financial officer of Bradley Pharmaceuticals, 201-882-1505/
 (BPRXA) CO: Bradley Pharmaceuticals, Inc. ST: New Jersey IN: MTC SU:


GK -- NY058 -- 6997 01/06/92 15:24 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 6, 1992
Words:399
Previous Article:SNYDER OIL DECLARES DIVIDEND
Next Article:GENERAL MOTORS DECLARES DIVIDEND
Topics:


Related Articles
Penford Corporation Announces Planned Spin-Off of Pharmaceuticals Business To Shareholders
Bradley Pharmaceuticals Completes Clinical Study That Successfully Supports the Effectiveness of Its Carmol(R) Scalp Treatment.
Bradley Pharmaceuticals Announces Second Significant Increase in Revenue And Earnings Projections for 2001.
Bradley Pharmaceuticals Anticipated Third Quarter Sales and Earnings Growth Estimated to Exceed Guidance.
Quintiles Completes Sale of Dermatology Assets to Bradley Pharmaceuticals.
Bradley Pharmaceuticals Announces Third Quarter 2004 Financial Statement Adjustment.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters